BackPanbela Therapeutics Overview

Panbela Therapeutics Operating Income

Track Panbela Therapeutics's operating income ($-44M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

-$14.33M
↑ 8.68% YoY

As of Sep 30, 2024

Annual Operating Income (TTM)

-$44.31M
↓ 40.42% YoY

Trailing 12 months ending Sep 30, 2024

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Panbela Therapeutics (PBLA) FAQ

Panbela Therapeutics posts a operating income of $-44M as of September 2024. That compares with $-32M in the prior-year period — down 40.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Panbela Therapeutics's operating income was $-32M. The latest reading is $-44M — a 40.4% year-over-year decrease (period ending September 2024). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of Panbela Therapeutics's financial statement story. At $-44M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PBLA's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Panbela Therapeutics's other metric pages and overview cover the third.

Judging Panbela Therapeutics against Technology peers is usually better than using a market-wide rule of thumb. Business models inside Technology are more comparable, which makes gaps in operating income easier to interpret. Start with $-44M here, then scan peer and history charts to see if the gap is persistent.